EMA finds no suicide risk with GLP-1 diabetes, obesity drugs
pharmaphorum
APRIL 14, 2024
EMA review finds no link between GLP-1 agonists used to treat diabetes and obesity and thoughts of suicide or self-injury.
Sun.Apr 14, 2024
109 
5 Promising MASH Therapies That Could Follow Madrigal’s Rezdiffra
BioSpace
APRIL 14, 2024
Metabolic dysfunction-associated steatohepatitis experts welcomed Madrigal’s Rezdiffra as an “important first," but there are more mid- to late-stage therapies showing promising results.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Acute Cardiac Events Among Hospitalized Older Adults With RSV Infection
JAMA Internal Medicine
APRIL 14, 2024
This cross-sectional study examines the frequency and severity of acute cardiac events in hospitalized adults aged 50 years or older with respiratory syncytial virus infection.
4 Investigational Weight Loss Drugs That Could Change the Market
BioSpace
APRIL 14, 2024
GLP-1 treatments are all the rage in this space, but they aren’t the only approach in development. The pipeline assets highlighted here offer a differentiated approach, potentially increasing efficacy or reducing side effects.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
SGLT2i vs Sulfonylureas for Gout Prevention Among Patients With Type 2 Diabetes Receiving Metformin
JAMA Internal Medicine
APRIL 14, 2024
This cohort study uses target trial emulation to evaluate risk of incident gout and rate of recurrent gout flares in patients with type 2 diabetes initiating sodium-glucose cotransporter-2 inhibitors (SGLT2i) vs sulfonylurea.
AbbVie Touts Long-Term Efficacy of Qulipta as Preventive Migraine Treatment
BioSpace
APRIL 14, 2024
AbbVie’s small molecule drug Qulipta has durable benefits and can reduce migraine frequency through 48 weeks of follow-up, according to interim Phase III data released on Friday.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Patented AI Platform Identifies Promising Early-Stage BioPharma Assets and Companies
BioSpace
APRIL 14, 2024
Fierce competition. Thin pipelines. Patent cliffs. The stakes are sky-high for pharmaceutical companies and investors alike.
New patent expiration for Takeda Pharms drug DEXILANT SOLUTAB
Drug Patent Watch
APRIL 14, 2024
Annual Drug Patent Expirations for DEXILANT+SOLUTAB Dexilant Solutab is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are six patents protecting this drug.
Listen Up: Emerging Vocal Biomarker Could Aid ALS Drug Development
BioSpace
APRIL 14, 2024
Experts are hopeful that objective biomarker measures for amyotrophic lateral sclerosis, such as the ones being developed by EverythingALS, will lead to more targeted, effective treatments.
New patent expiration for Astrazeneca Ab drug FARXIGA
Drug Patent Watch
APRIL 14, 2024
Annual Drug Patent Expirations for FARXIGA Farxiga is a drug marketed by Astrazeneca Ab and is included in one NDA. It is available from five suppliers.
Regeneron Launches $500M Venture Capital Fund Skewed Toward Biotech
BioSpace
APRIL 14, 2024
While the VC fund launched on Monday by Regeneron Pharmaceuticals has an investment mandate that includes healthcare broadly, Regeneron Ventures will lean towards biotechnology, devices, tools and enabling technologies.
New patent for Norton Waterford drug QVAR REDIHALER
Drug Patent Watch
APRIL 14, 2024
Annual Drug Patent Expirations for QVAR+REDIHALER Qvar Redihaler is a drug marketed by Norton Waterford and is included in one NDA. It is available from three suppliers.
Genentech Walks Away From $3B Allogeneic T-Cell Pact with Adaptimmune
BioSpace
APRIL 14, 2024
Roche’s Genentech subsidiary is terminating for undisclosed reasons its 2021 contract with Adaptimmune for the development of allogeneic T-cell therapeutics.
New patent for Astrazeneca drug TAGRISSO
Drug Patent Watch
APRIL 14, 2024
Annual Drug Patent Expirations for TAGRISSO Tagrisso is a drug marketed by Astrazeneca and is included in one NDA. It is available from one supplier.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
FDA Adcomm Backs New Surrogate Endpoint for Accelerated Approvals in Blood Ca.
BioSpace
APRIL 14, 2024
An FDA advisory committee on Friday agreed that using minimal residual disease could be a viable surrogate endpoint for accelerated approval for drug development in multiple myeloma.
New patent for Azurity drug EPRONTIA
Drug Patent Watch
APRIL 14, 2024
Annual Drug Patent Expirations for EPRONTIA Eprontia is a drug marketed by Azurity and is included in one NDA. It is available from one supplier.
FDA Puts Clinical Hold on Neumora’s Schizophrenia Drug Due to Preclinical Saf.
BioSpace
APRIL 14, 2024
Following cases of convulsions in rabbits in a preclinical study, the FDA has placed a clinical hold on Neumora Therapeutics’ Phase I schizophrenia drug candidate NMRA-266.
Drug Patent Expirations for the Week of April 14, 2024
Drug Patent Watch
APRIL 14, 2024
DEXILANT (dexlansoprazole) Takeda pharms usa Patent: 8,722,084 Expiration: Apr 15, 2024 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.
Electronic Health Record Population Health Management for Chronic Kidney Disease Care
JAMA Internal Medicine
APRIL 14, 2024
This cluster randomized clinical trial examines the effectiveness of an electronic health record–based population health management intervention vs usual care for reducing chronic kidney disease progression.
Which pharmaceutical companies have the most drug patents in New Zealand?
Drug Patent Watch
APRIL 14, 2024
This chart shows the pharmaceutical companies with the most patents in New Zealand.
Roche Bispecific T-Cell Engager Improves Survival in Lymphoma, Teeing up Label Expansion
BioSpace
APRIL 14, 2024
Roche said Monday that its bispecific T cell engager Columvi improved survival in a Phase III lymphoma trial, clearing the drugmaker to seek a full, expanded label that could drive sales growth.
Adverse Pregnancy Outcomes and Long-Term Mortality in Women
JAMA Internal Medicine
APRIL 14, 2024
This cohort study aims to determine long-term mortality risks associated with 5 major adverse pregnancy outcomes in a large population-based cohort of women.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Let's personalize your content